Ganymed Robotics Announces Appointment of Seasoned Leadership Team to Bring to Market Its Next Generation Surgical Technology
3.10.2023 09:30:00 EEST | Business Wire | Press release
Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, is happy to announce a series of senior leadership appointments to drive the company’s growth as it prepares for industrialization and commercial launch. The firm has appointed 5 seasoned executives to lead strategic and operational developments across all key functions, ranging from product development to regulatory and market access, finance, human resources and legal. Former companies include ZimmerBiomet, Alphatec, EOS Imaging, Corwave, Beckton Dickinson, Robocath, Médecins Sans Frontières.
The composition of the new Executive Committee exhibits strong expertise in both launching innovative medical devices and scaling medtech companies, as well as gender parity. It is composed of 8 members : Sophie Cahen, CEO and co-founder, Silvère Lucquin, Chief Operating Officer, and Michel Vernizeau, VP R&D, and 5 seasoned new members: Lukas Vancura as VP Product Marketing, Clémentine Liard as VP Quality Assurance and Regulatory Affairs (QARA), Sandra Demol as Human Resources Director, Julien Puaux as VP Finance and Juliette Loget as General Counsel. These additions to the Executive Committee reflect Ganymed’s continued attractiveness for talents of all seniority, and its commitment to bringing its game-changing arthroplasty robot into operating rooms as quickly as possible.
“I am delighted to partner with such talented senior executives who bring to the company their impressive experience and recognized expertise, as we accelerate the development of our revolutionary patented technology platform and prepare for industrialization and launch of our first surgical robotic assistant for knee arthroplasty,” says Sophie Cahen. “The arrival of the leadership team’s newest members is a testimony of the swift growth that Ganymed accomplished over the past 18 months, both on the scientific and operational fronts, and speaks to a team united by a profound sense of shared purpose.”
Ganymed Robotics’ ambition is to democratize access to quality care in hard tissue surgery. The company aims to secure and standardize a complex surgical gesture, so that each patient gets the right, personalized care. The first application is a co-manipulated surgical robotic assistant for total knee arthroplasty (TKA). It has developed a proprietary technology platform built around two disruptive innovations: contactless localization of the bones and human-machine collaborative movement.
Over the past 18 months, Ganymed reached several major milestones, attesting of its ability to efficiently implement its growth strategy: it completed a 36 M€ Series B fundraising round with a high-profile group of healthcare investors, welcomed two world renowned independent members on its Board of Directors, Michel Therin et Mike Lobinsky, doubled the size of its team across all functions to reach 40 persons today, secured strategic partnerships, moved forward with regulatory and marketing developments, won new national and international innovation awards, and ran successful pre-clinical tests. With the arrival of high-profile senior executives on its leadership team, Ganymed is ideally positioned to successfully accelerate the execution of its strategic, industrial, and operational development plan.
About Ganymed Robotics
Ganymed Robotics is a medical device company founded in 2018, developing the next generation of robotic assistance technologies for orthopedic surgery. The company’s mission is to improve patient outcome, surgeon experience, and overall efficiency of care delivery for its target indications. Based in Paris, Ganymed Robotics currently employs 40 people who develop a proprietary technology platform combining computer vision, a branch of artificial intelligence, and mechatronics, in close collaboration with world-class clinicians and advisors. The first application is a robotic surgical assistant for knee arthroplasties, a common and fast-growing intervention associated with high dissatisfaction rates of above 20%. Ganymed Robotics intends to progressively deploy its technology to address several other orthopedics indications. Ganymed Robotics won national and international innovation awards, such as I-Nov, I-Lab, French Tech DeepNum20, French Tech Emergence, Deep Tech Pioneer, EIT Health, Wilco, EIC Accelerator. For more information: www.ganymedrobotics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231002032667/en/
Contact information
Press
Strategies & Image (S&I)
Anne Rein
+33 6 03 35 92 05
anne.rein@strategiesimage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Helps Customers Accelerate Adoption of Latest VMware Cloud Foundation Innovations2.9.2026 23:30:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, announced new capabilities in NetApp ONTAP® have been tested and validated to support VMware Cloud Foundation (VCF) 9.1, giving customers an optimized and secure data infrastructure foundation for their private and hybrid clouds. By combining the advanced capabilities of VCF 9.1 with cost-effective and enterprise data management with built-in security features from NetApp, including safeguarding data against ransomware attacks with rapid recovery, mutual customers can lower costs and accelerate the deployment of their AI software into production. VMware Cloud Foundation 9.1 provides enterprises with a unified private cloud platform for running both traditional and modern workloads. NetApp's solutions are tested and validated to support VCF 9.1 environments, enabling mutual customers to immediately begin taking advantage of VCF 9.1 innovations when they upgrade, with a data infrastructure layer already proven to work w
Venture Global Announces Closing of $3,000,000,000 364-Day Senior Secured Revolving Credit Facility2.9.2026 23:30:00 EEST | Press release
Venture Global, Inc. (“Venture Global”) announced today that its subsidiary Venture Global LNG, Inc. (“VGLNG”) has entered into a new, $3,000,000,000 364-day revolving credit facility (the “Facility”). Venture Global expects to use the proceeds from borrowings under the Facility for general corporate purposes of VGLNG and its subsidiaries, including to fund certain project costs for the CP2 and Plaquemines bolt-on expansions prior to their respective FIDs. Bank of America, N.A. served as Coordinating Lead Arranger and Sole Bookrunner and will also serve as Administrative Agent. BBVA, Goldman Sachs, ING, J.P. Morgan, Mizuho, MUFG, NBC, RBC, Scotia, SMBC, U.S. Bank, and Wells Fargo served as Coordinating Lead Arrangers and Barclays, Santander, and Deutsche Bank served as Joint Lead Arrangers. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Vent
Invivoscribe Begins Commercial Shipments of PrepQuant ™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing2.9.2026 22:31:00 EEST | Press release
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. First unveiled at the American Association for Cancer Research Annual Meeting in April 2026, PrepQuant is now being delivered to customers, marking the platform's progression from development and validation into commercial deployment. The commercial milestone extends Invivoscribe's capabilities into laboratory instrumentation and addresses a critical bottleneck in highly sensitive molecular testing: efficiently recovering, concentrating, and quantifying DNA from larger blood and plasma inputs. PrepQuant is assay agnostic, designed to produce concentrated genomic DNA and cell-free DNA (cfDNA) suitable for a full range of downstream molecular workflows, including MRD assays intended to detect very low levels of residual disease. MRD Sensitivity Starts Before the Assay As MRD testing moves tow
C.H. Guenther Opens Centre of Excellence in Coventry, UK to Accelerate Bakery Innovation and Support Future Manufacturing Growth Across UK and Europe2.9.2026 19:00:00 EEST | Press release
C.H. Guenther & Son LLC (“C.H. Guenther” or “CHG”), a leading food manufacturer, has opened a new Centre of Excellence (the “Centre”) at its flagship Coventry bakery, creating a dedicated innovation and customer collaboration hub designed to accelerate the development of premium bakery products across the UK and Europe. The new facility has been designed to support CHG’s customers including leading global quick service restaurants, foodservice operators and retailers as they develop, test and refine new bakery products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902696890/en/ The purpose-built, 172-square-metre Centre of Excellence brings together a commercial-scale bakery, customer demonstration kitchen, sensory evaluation facilities, innovation suite and dedicated collaboration spaces in one specialized location. Designed to support and accelerate product development from concept through to commercial manufacturing,
Record Asset Management Enters New Phase of Growth2.9.2026 18:35:00 EEST | Press release
Record Asset Management GmbH (“RAM”), a subsidiary of London-listed Record plc (“Record” or the “Group”), is pleased to announce that it is now operating cashflow positive, thereby marking a transition from its investment phase into a growth business within the Group, and a significant milestone towards sustainable profitability. RAM is the European asset management arm of Record, the London-listed specialist investment group managing USD 122 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. RAM was established as a sister company to Record’s core currency business and obtained its BaFin license in 2022. RAM has grown rapidly in the last two years and has developed into a diversified private markets platform with dedicated infrastructure e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
